Saturday, September 23, 2023
Saturday, September 23, 2023

PulseSelect Pulsed Field Ablation System by Medtronic: 1st Procedures in Pivotal Trial Reported

March 4, 2021

PulseSelect Pulsed Field Ablation System is a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation (AF).

The first procedure in the PULSED AF pivotal trial was performed this week at Southcoast Health by Nitesh Sood, M.D., Fall River, Massachusetts; the second procedure was performed by Arnoldas Giedrimas, M.D., also at Southcoast Health. The PULSED AF Trial is the first global, pre-market, multi-center clinical study with IDE approval aimed to establish the safety and efficacy of the PulseSelect System.

Developed exclusively at Medtronic, the PulseSelect Pulsed Field Ablation System delivers pulsed electric fields through an ablation catheter designed specifically to interrupt irregular electrical pathways in the heart that trigger atrial fibrillation. However, unlike traditional methods of ablation that heat (radiofrequency ablation) or cool (cryoablation) the atrial tissue, the PulseSelect System uses a non-thermal approach and preferentially targets heart tissue with the goal of avoiding unwanted injury to surrounding structures, a risk of current ablation technologies.

“Based on the results we’ve experienced with the pilot trial, we are entering a new era for AF ablation techniques with this novel energy source,” said Atul Verma, M.D., electrophysiologist and head of arrhythmia services at Southlake Regional Health Centre in Newmarket, Canada and the principal investigator (PI) for the PULSED AF study. “We are excited to begin the pivotal stage of the PULSED AF study and generate a larger body of clinical evidence to support the safety and benefits of pulsed field ablation.”

Atrial fibrillation is one of the most common and undertreated heart rhythm disorders, affecting more than 37 million people worldwide.1 The disease involves an irregular quivering or rapid heart rhythm in the upper chambers of the heart. A heart in AF beats significantly faster than one in normal rhythm. AF is a progressive disease that gets worse over time and can increase the risk for stroke and related heart problems.2

The PULSED AF trial is a prospective, non-randomized, multi-center clinical trial that will enroll up to 500 patients who will be treated with the PulseSelect System across as many as 50 sites in the U.S., Canada, Europe, and Australia. PULSED AF is designed to evaluate the safety and efficacy of the PulseSelect System for the treatment of AF in adult patients with a history of drug refractory, recurrent and symptomatic paroxysmal or persistent AF. Patients will be assessed at six and 12 months.

“For years, Medtronic has been an active leader in the investigation of the safety and efficacy of pulsed field ablation,” said Rob Kowal, M.D., Ph.D., chief medical officer of Cardiac Ablation Solutions, which is reported as part of the Cardiac and Vascular Group at Medtronic. “Developed internally at Medtronic, the PulseSelect System has the potential to create a paradigm shift in how cardiac ablations are performed for patients suffering from atrial fibrillation.”

Pre-clinical research on the PulseSelect technology has included extensive work to understand the physiology and mechanism of action for this novel energy source, resulting in its designation in 2018 as a Breakthrough Device from the U.S. Food and Drug Administration (FDA) for the treatment of drug refractory recurrent symptomatic atrial fibrillation. PulseSelect was designated with Innovative Device Status, also known as Green Channel, in November 2020 by the Center for Medical Device Evaluation (CMDE), the arm of the National Medical Products Administration (NMPA) that sets medical device regulations for China.

Results of the PULSED AF pilot study were presented in a late-breaking session at Heart Rhythm Society 2020 Science and additional evidence was shared at the AF Symposium in January 2021, demonstrating 100 percent acute efficacy and no device or procedural-related events in the pilot cohort of patients. Worldwide, the PulseSelect system is investigational and not approved for sale or distribution.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures.

Annalise.ai Receives FDA Clearance and Breakthrough Device Designation

Annalise.ai has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy